Mission Bio Stock
Mission Bio develops only single-cell multi-omics platform integrating genotype and phenotype for cancer research and biomarker development.
Sign up today and learn more about Mission Bio Stock
Invest in or value your shares in one or many pre-IPO companies through an EquityZen investment vehicle.
About Mission Bio Stock
Mission Bio delivers targeted solutions for high-impact applications with the Tapestri Platform. The Tapestri Platform is the industry’s first and only single-cell multi-omics platform, enabling genotype and phenotype from the same cell and precise detection of heterogeneity in disease progression and treatment response. Application areas include oncology blood cancers, solid tumors, and genome editing validation.
Funding History
| October 2017 | $10.0M |
|---|---|
| December 2018 | $30.0M |
| August 2020 | $70.0M |
Management
Chief Technology Officer & SVP of Operations
Nigel P. Beard
CFO
Marcel Roche
Chief Commercial Officer
Darrin Crisitello
Co-Founder & Director of Engineering
Adam Sciambi
CEO & Co-founder
Charlie Silver
Press
businesswire - Apr, 6 2024
Mission Bio Launches Sample Multiplexing for Tapestri to Unlock Critical Single-Cell Insights for Oncology and ...linkedin - Apr, 6 2024
Ursheet P. on LinkedIn: Delighted to have Brian Kim as the new CEO of Mission Bio. Brian brings a…biospace - Apr, 6 2024
Mission Bio Launches Sample Multiplexing for Tapestri to Unlock Critical Single-Cell Insights for Oncology and Genome Editing Marketscontractpharma - Feb, 18 2024
Mission Bio Names Brian Kim CEOhitconsultant - Feb, 18 2024
Mission Bio Appoints Brian Kim as CEO to Spearhead Single-Cell Genomic SolutionsEquityZen Recognized As:
